# Evaluation of Serum Sestrin 2 Levels in Patients Diagnosed with Endometrial Polyps and Uterine Leiomyomas

## TL;DR

This study explores whether Sestrin 2 in blood can help detect endometrial polyps and uterine leiomyomas early.

## Contribution

The study identifies elevated serum Sestrin 2 levels as a potential novel biomarker for early diagnosis of gynecological conditions.

## Key findings

- Serum Sestrin 2 levels were significantly higher in patients with endometrial polyps and uterine leiomyomas.
- These elevated levels suggest Sestrin 2 could serve as an early diagnostic biomarker for these conditions.

## Abstract

Background/Objectives: This study investigates the correlation between the serum levels of Sestrin 2 and the presence of endometrial polyps or uterine leiomyomas, aiming to enhance the understanding of the pathophysiology underlying these gynecological conditions and evaluate the potential of Sestrin 2 as an early diagnostic biomarker. Methods: In a prospective case-control format, patients with preliminary diagnoses of endometrial polyps or uterine leiomyomas confirmed by histopathological analysis following surgery were included. This study analyzed serum Sestrin 2 levels across different patient groups, revealing significant variations that underscore the diagnostic value of Sestrin 2. Results: Elevated serum Sestrin 2 levels were observed in patients with endometrial polyps and uterine leiomyomas compared to the control group, suggesting its utility as a novel marker for early detection. Conclusions: The study indicates the promising role of serum Sestrin 2 levels as a valuable biomarker for early diagnosis of endometrial polyps and uterine leiomyomas, advocating for further research into its diagnostic and therapeutic potential.